Cyclopentyl Or Cyclopentene (e.g., Prostaglandins, Etc.) Patents (Class 514/573)
-
Publication number: 20120190620Abstract: The present invention discloses methods to identify targets, pathways and molecules regulating purinosomes and their uses for treating pathophysiological disorders associated with purinosomes. Disclosed are methods related to both label-free cellular assays and fluorescence imaging to confirm the regulatory roles of various targets and molecules in purinosome dynamics. Disclosed are methods to classify molecules and the uses of these molecules for different indications. Specifically, the purinosome-disrupting molecules can be used for improved prevention and treatment of cancer development.Type: ApplicationFiled: July 18, 2011Publication date: July 26, 2012Inventors: Stephen Benkovic, Ye Fang, Songon An, Florence Verrier
-
Patent number: 8227514Abstract: Travoprost medicament compositions for non-daily topical application are useful for simulating or inducing the growth and/or decreasing the loss and/or increasing the density and/or reducing the heterogeneity in the diameter of human hair shafts/follicles, e.g., for the treatment of androgenic alopecia, such medicament compositions being at least twice applied over a time interval of greater than 24 hours.Type: GrantFiled: February 23, 2010Date of Patent: July 24, 2012Assignee: Galderma Research & DevelopmentInventors: Sandrine Rethore, Carine Rosignoli, André Jomard, Johannes Voegel
-
Publication number: 20120184500Abstract: This invention relates to the use of an oral composition comprising Stevia extract, steviol precursors, or steviol which enhances the appearance of hair. It further relates methods of improving the appearance of hair by oral administration of an effective amount of Stevia extract, steviol precursors or steviol.Type: ApplicationFiled: July 20, 2010Publication date: July 19, 2012Inventors: Regina Goralczyk, Annis Olivia Mayne-Mechan, Jenny Piussi, Henry Rieger, Hasan Mohajeri
-
Publication number: 20120178798Abstract: Disclosed herein are compounds having a formula: Therapeutic methods, medicaments, and compositions related thereto are also disclosed.Type: ApplicationFiled: March 19, 2012Publication date: July 12, 2012Applicant: ALLERGAN, INC.Inventor: Robert M. BURK
-
Publication number: 20120177717Abstract: Disclosed is a drug delivery system for delivering a drug at a sustained constant rate for a long period, which can be transplanted into an affected part safely and in a simple manner and can deliver a drug to the affected part for a long period. Specifically disclosed is a sustained drug delivery system in which an implant is implanted into a body, wherein the implant is a PEG capsule comprising a box-shaped PEG and a porous PEG sheet.Type: ApplicationFiled: February 16, 2012Publication date: July 12, 2012Applicant: TOHOKU UNIVERSITYInventors: Toshiaki ABE, Nobuhiro NAGAI, Hirokazu KAJI, Takeaki KAWASHIMA, Matsuhiko NISHIZAWA, Koji NISHIDA
-
Publication number: 20120177699Abstract: A preparation method of drug loaded emulsion is disclosed. The method comprises the steps of: preparing a non-self emulsifying O/W blank emulsion having no active ingredients; then, adding therapeutically effective amount of active ingredients to the 0/W blank emulsion, adjusting pH to distribute the active ingredients through the membrane to obtain the desired emulsion.Type: ApplicationFiled: June 3, 2010Publication date: July 12, 2012Applicants: SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD., JIANGSU HENGRUI MEDICINE CO., LTD.Inventors: Xinyong Tong, Haifeng Wang, Li Lu, Liang Chen, Yuan Shi
-
Patent number: 8207223Abstract: A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).Type: GrantFiled: August 27, 2009Date of Patent: June 26, 2012Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Toru Maruyama, Kaoru Kobayashi, Tohru Kambe, Takayuki Maruyama, Hideyuki Yoshida, Akio Nishiura, Nobutaka Abe
-
Patent number: 8202909Abstract: The present invention provides a method for treating a central nervous system disorder in a mammalian subject, which comprises administering an effective amount of a 11-deoxy-prostaglandin compound to a subject in need thereof. The invention also provide novel 11-deoxy-prostaglandin compound.Type: GrantFiled: January 26, 2006Date of Patent: June 19, 2012Assignee: Sucampo AGInventor: Ryuji Ueno
-
Publication number: 20120149655Abstract: A formulation or composition contractility comprising jasmonate for modulating bladder and/or treating bladder dysfunction, particularly an overactive bladder in a mammal, particularly a human and use of jasmonate for treating bladder dysfunction is provided.Type: ApplicationFiled: December 9, 2011Publication date: June 14, 2012Applicant: BROADY HEALTH SCIENCES, LLCInventor: Brunde Broady
-
Publication number: 20120131700Abstract: The invention provides seed treatment compositions as well as their use, methods for treating seeds, methods of protecting plants against pests and also treated seeds and plants. In one embodiment there is provided a method of treating a seed with a seed treatment composition to induce a plant resistance mechanism against one or more pests in a plant grown from said seed.Type: ApplicationFiled: January 12, 2012Publication date: May 24, 2012Applicant: Plant Bioscience LimitedInventors: Michael Richard Roberts, Nigel Duncan Paul, Jane Elizabeth Taylor, Patricia Croft, Jason Paul Moore
-
Publication number: 20120129930Abstract: The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's disease, Syndrome X, peroxisome proliferator activated receptor related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: ApplicationFiled: November 15, 2011Publication date: May 24, 2012Applicant: Esperion Therapeutics, Inc.Inventors: Jean-Louis Henri DASSEUX, Daniela Carmen ONICIU
-
Patent number: 8183291Abstract: A clear ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V), 0.003 to 0.01% (W/V) benzalkonium chloride and at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic. A method of preventing white turbidity in an ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V) and 0.003 to 0.01% (W/V) benzalkonium chloride, the method involving adding to the solution at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic.Type: GrantFiled: August 26, 2010Date of Patent: May 22, 2012Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Hiroyuki Asada, Akio Kimura
-
Publication number: 20120122976Abstract: The invention relates to a phosphate-free pharmaceutical composition which comprises at least one FP prostanoid receptor agonist and/or at least one prostamide receptor agonist and also citrate salts and/or citric acid.Type: ApplicationFiled: May 14, 2010Publication date: May 17, 2012Applicant: URSAPHARM ARZNEIMITTEL GMBHInventor: Frank Holzer
-
Patent number: 8168680Abstract: A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.Type: GrantFiled: February 8, 2011Date of Patent: May 1, 2012Assignee: Allergan, Inc.Inventors: Yariv Donde, Robert M. Burk, Michael E. Garst
-
Publication number: 20120088824Abstract: A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention includes a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects.Type: ApplicationFiled: December 20, 2011Publication date: April 12, 2012Applicant: SUCAMPO AGInventors: Ryuji UENO, Myra L. PATCHEN
-
Publication number: 20120088836Abstract: The invention relates to a method for cosmetically treating oily skin, including the topical application onto the skin of a composition containing a jasmonic acid compound in a physiologically acceptable medium.Type: ApplicationFiled: July 1, 2010Publication date: April 12, 2012Applicant: L'OREALInventor: Maria Dalko
-
Publication number: 20120076848Abstract: Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are nanoparticle compositions for lightening the pigmented tissues or treating a pigmented tissue related disease.Type: ApplicationFiled: July 21, 2010Publication date: March 29, 2012Inventor: Kambiz Thomas Moazed
-
Patent number: 8143312Abstract: An object of the present invention is to provide better formulations of a latanoprost ophthalmic solution. The present invention provides a clear ophthalmic solution comprising latanoprost as an active ingredient and benzalkonium chloride as a preservative wherein white turbidity due to a change of formulation is prevented by at least one means selected from the following 1) to 3); 1) adding a surfactant, 2) using benzalkonium chloride represented by the formula of [C6H5CH2N(CH3)2R]Cl (wherein R is alkyl having 12 carbon atoms) as the preservative and 3) adding a nonionic tonicity agent as a tonicity agent.Type: GrantFiled: September 8, 2003Date of Patent: March 27, 2012Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Hiroyuki Asada, Akio Kimura
-
Publication number: 20120071528Abstract: The invention is directed to novel compounds of Formula I: as well as its stereoisomers and/or pharmaceutically acceptable salts, for the treatment of diabetes and diabetes associated dyslipidemia.Type: ApplicationFiled: September 20, 2011Publication date: March 22, 2012Applicant: KAREUS THERAPEUTICS, SAInventors: Ish Khanna, Sivaram Pillarisetti
-
Publication number: 20120070369Abstract: The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders.Type: ApplicationFiled: December 10, 2009Publication date: March 22, 2012Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Othon Iliopoulos, Michael Zimmer
-
Publication number: 20120058087Abstract: The present invention relates to methods for diagnosing and treatment of a dormant infection of at least one pathogen. The invention further relates to a composition comprising an anti-dormancy factor as well as to said composition for use in a method of diagnosis or treatment and also to a method for manufacturing said composition. The invention further relates to a kit of parts comprising, inter alia, said composition. The invention also relates to a method for activating a dormant infection.Type: ApplicationFiled: December 18, 2009Publication date: March 8, 2012Applicant: Kobenhavns UniversitetInventors: Morten Rønn Petersen, Anders Miki Bojesen
-
Publication number: 20120040901Abstract: The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an amphiphilic ammonium-type component, which precipitate is obtainable by a process including the following steps: 1. contacting the anionic polymeric component and an cyclodextrin component in an aqueous medium, and 2. adding to the mixture obtained in step 1 said amphiphilic ammonium-type component, wherein said components are present in amounts effective to form said precipitate, and preferably to corresponding precipitates additionally comprising said cyclodextrin component. Both types of precipitates may optionally comprise one or more further components. The precipitates are particularly useful as controlled-release depot formulations suitable for long-lasting delivery of said further components.Type: ApplicationFiled: October 25, 2011Publication date: February 16, 2012Inventors: Lajos Szente, Jozsef Szejtli, György Lajos Kis, Christian Schoch
-
Patent number: 8114911Abstract: Provided is a composition for treating obesity which comprises an effective amount of a prostaglandin compound, especially, a compound of formula (I).Type: GrantFiled: October 22, 2003Date of Patent: February 14, 2012Assignee: Sucampo AGInventor: Ryuji Ueno
-
Publication number: 20120034321Abstract: The invention provides methods for treating ophthalmic disorders comprising at least one nitric oxide enhancing prostaglandin compound or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The nitric oxide enhancing prostaglandin compounds comprise at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group.Type: ApplicationFiled: October 18, 2011Publication date: February 9, 2012Inventor: David S. Garvey
-
Patent number: 8106096Abstract: The present invention provides a method for treating or reducing damage to the optic nerve in a subject comprising administering to the subject a therapeutically effective amount of prostaglandin J2 alone or in combination with an effective amount of GM-CSF. In particular aspects of the invention, the subject is a mammal, and in further aspects the mammal is a human.Type: GrantFiled: March 12, 2009Date of Patent: January 31, 2012Assignee: University of Maryland, BaltimoreInventor: Steven L Bernstein
-
Publication number: 20120022164Abstract: Provided is an external preparation comprising a complex containing: any one of a prostaglandin derivative, a pharmaceutically acceptable salt thereof and a hydrate thereof; and cyclodextrin, the prostaglandin derivative being represented by the following formula (I): (where R represents a group represented by the formula: —(CH2)4—S—CH2—CO2H, —(CH2)4—S—CH2—CO2CH3, —(CH2)4—C?C—CO2H, —CH2—S—(CH2)2—S—CH2—CO2H, or —CH2—S—(CH2)4—CO2H), so that storage stability and content uniformity of the compound of the formula (I) are ensured.Type: ApplicationFiled: July 25, 2011Publication date: January 26, 2012Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Takayuki SATO, Yoshie SATO
-
Patent number: 8097653Abstract: A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention comprises a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects.Type: GrantFiled: November 14, 2002Date of Patent: January 17, 2012Assignee: Sucampo AGInventors: Ryuji Ueno, Myra L. Patchen
-
Publication number: 20120003189Abstract: This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.Type: ApplicationFiled: November 6, 2009Publication date: January 5, 2012Inventors: Louis M. Pelus, Jonathan Hoggatt, Pratibha Singh
-
Patent number: 8084501Abstract: A pharmaceutical composition containing a prostaglandin and an alkanoic acid ester of a polyethoxylated sorbitol in an amount effective to enhance the chemical stability of the prostaglandin, and the use thereof for treating ophthalmic conditions. Also disclosed are methods for enhancing the chemical stability of a prostaglandin-containing composition by using an alkanoic acid ester of a polyethoxylated sorbitol.Type: GrantFiled: January 20, 2006Date of Patent: December 27, 2011Assignees: Breath Limited, Resolution Chemicals LimitedInventors: Victor Deaciuc, Michael Hagan, Hashem Heiati, Karen K. Jette, Gary C. Visor, Ian G. C. McAffer, Peter Tasko
-
Publication number: 20110305731Abstract: The present invention refers to pharmaceutical compositions comprising a jasmonic acid derivative and a carrier, preferably cyclodextrin or a polyamidoamine. The compositions may be used for treating cancer.Type: ApplicationFiled: May 28, 2009Publication date: December 15, 2011Inventor: Jose Emilio Fehr Pereira Lopes
-
Publication number: 20110301105Abstract: We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells such as skin-derived precursors (SKPs)). The invention therefore invention provides compositions, methods, and kits for increasing proliferation of cells, using compounds that decrease p63 expression or activity or using the compounds described herein. The invention also features methods of using these compounds for increasing hair growth, improving skin health, or promoting skin repair in a subject.Type: ApplicationFiled: March 30, 2011Publication date: December 8, 2011Applicant: The Hospital for Sick ChildrenInventors: Freda Miller, David Kaplan, Kristen Smith, Maryline Paris, Sibel Naska
-
Publication number: 20110287116Abstract: A formulation comprising jasmonate for improving cardiac muscle function, particularly by modulating myocardial contractility in a subject is disclosed. Such a formulation may be used to treat a heart or cardiac related disorder.Type: ApplicationFiled: May 18, 2011Publication date: November 24, 2011Applicant: BROADY HEALTH SCIENCES LLCInventor: Brunde Broady
-
Patent number: 8063240Abstract: A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.Type: GrantFiled: November 14, 2008Date of Patent: November 22, 2011Assignee: Cayman Chemical Company, IncorporatedInventors: Nancy S. Barta, Stephen D. Barrett, Gregory W. Endres, Andriy M. Kornilov, Kirk M. Maxey, Adam Uzieblo
-
Publication number: 20110280813Abstract: The invention is related to various methods for inhibiting or reducing biofilm formation, treating a biofilm production-related disorder, preventing biofilm formation, and screening for neuraminidase inhibitors.Type: ApplicationFiled: November 13, 2009Publication date: November 17, 2011Inventors: Alice Prince, Liang Tong
-
Publication number: 20110269691Abstract: A method of treating a hypopigmentary condition in a subject comprising administering to the subject an amount of SOX9 sufficient to treat melanoma is disclosed. The hypopigmentary condition can be a result of surgery, trauma or vitiligo. A method of treating a hyperpigmentary condition in a subject comprising administering to the subject an amount of inhibitor of SOX9 activity sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising administering to the subject an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising increasing the amounts of retinoic acid and SOX9 in the subject by amounts sufficient to treat melanoma. A method of treating melanoma in a subject comprising administering to the subject an amount of prostaglandin D2 (PGD2) and retinoic acid (RA) sufficient to treat cancer.Type: ApplicationFiled: August 15, 2008Publication date: November 3, 2011Inventors: Vincent J. Hearing, Thierry Passeron
-
Publication number: 20110263498Abstract: A pharmaceutical composition for enhancing male erectile function comprising an erectile function-enhancing amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatmedin-C) and analogue LR3 IGF1 in admixture with a pharmaceutically-acceptable diluents or carrier. Such compositions optionally further comprise compounds selected from an androgen, particularly, testosterone and dihydrotestosterone, a vasodilator, PDE5 inhibitor and prostaglandin E1.Type: ApplicationFiled: November 5, 2009Publication date: October 27, 2011Inventor: Kenneth W. Adams
-
Publication number: 20110257263Abstract: The invention provides methods for isolating and enhancing the levels of jasmonates from cacao plant sources. In a preferred embodiment, jasmonic acid and 12-hydroxy jasmonate sulfate are detected in various cocoa products, and the levels of these compounds can be manipulated to increase the beneficial health effects of a food product made with the cocoa products The invention includes methods to prepare edible products containing cocoa jasmonates.Type: ApplicationFiled: August 27, 2009Publication date: October 20, 2011Inventors: William Jeffrey Hurst, David A. Stuart, Angela Isabela Calderon Justavino, Richard B. Van Breemen
-
Publication number: 20110250142Abstract: Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and a second antihypertensive agent (preferably a calcium antagonist, an ACE inhibitor, or an angiotensin II receptor antagonist) for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome.Type: ApplicationFiled: March 1, 2011Publication date: October 13, 2011Inventors: Benson M. Fong, Glen V. Cornett
-
Patent number: 8022250Abstract: 1-Phenylalkanecarboxylic acid derivatives, the processes for the preparation thereof and the use thereof in the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease.Type: GrantFiled: December 24, 2009Date of Patent: September 20, 2011Assignee: Chiesi Farmaceutici S.p.A.Inventors: Luca Raveglia, Ilaria Peretto, Stefano Radaelli, Bruno Pietro Imbimbo, Andrea Rizzi, Gino Villetti
-
Patent number: 8003680Abstract: Disclosed herein are compounds of the formula therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: September 8, 2009Date of Patent: August 23, 2011Assignee: Allergan, Inc.Inventors: David W. Old, Vinh X. Ngo
-
Patent number: 7998507Abstract: Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.Type: GrantFiled: December 7, 2005Date of Patent: August 16, 2011Assignee: Elan Pharma International Ltd.Inventors: H. William Bosch, Greta G. Cary, Douglas C. Hovey, Rajeev A. Jain, Laura J. Kline, Elaine Merisko-Liversidge, Kevin D. Ostrander, Niels P. Ryde, Stephen B. Ruddy
-
Publication number: 20110195987Abstract: Methods of treating disorders with cholinergic agonists for example, muscarinic receptor agonists such as pilocarpine and cevimeline are provided. In particular, methods of treating and/or preventing interstitial cystitis, yeast infections, urinary tract infections, atrophic vaginitis, vaginal dryness, and sexual dysfunction associated with vaginal dryness by administering a cholinergic agonist to the subject suffering from the disorders are provided. In addition, intra-vaginal administration of cholinergic agonists such as muscarinic receptor agonists to patients suffering from interstitial cystitis, vaginal dryness, and sexual dysfunction associated with vaginal dryness is also provided.Type: ApplicationFiled: October 5, 2010Publication date: August 11, 2011Inventors: Thomas NAJARIAN, Kathyrn Susan UNKEL
-
Publication number: 20110184358Abstract: The present invention is directed to a pulsatile ophthalmic peri-corneal drug delivery device. The device includes an annular body and a mechanism for releasing multiple separate and distinct doses of a therapeutic composition over an extended period of time.Type: ApplicationFiled: January 25, 2011Publication date: July 28, 2011Inventors: Alan L. Weiner, Bhagwati P. Kabra
-
Publication number: 20110172177Abstract: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under the brand Xalatan™ and Compound A.Type: ApplicationFiled: January 11, 2011Publication date: July 14, 2011Applicant: INOTEK PHARMACEUTICALS CORPORATIONInventors: Norman N. KIM, William K. MCVICAR, Thomas G. McCAULEY, Rudolf A. BAUMGARTNER
-
Publication number: 20110172308Abstract: The present invention relates to methods for identifying candidate therapeutics for hypertension. The invention further provides a method for treating hypertension and/or decreasing atherogenesis by administration of an inhibitor of PGF2? receptor.Type: ApplicationFiled: March 9, 2009Publication date: July 14, 2011Applicant: The Trustees of The University of PennsylvaniaInventors: Garret A. Fitzgerald, Ying Yu, Margaret Lucitt
-
Publication number: 20110151028Abstract: A topical pharmacological preparation in the form of cream, suppositories or drops delivered topically to the vagina in order to contract the smooth muscle of the vaginal wall. The preparation contains a smooth muscle contracting agent such as oxytocin capable of constrict the vaginal tube reducing its overall diameter for a more pleasurable sexual experience for the female subject and his partner alike. The smooth muscle contracting agent can be associated with a systemic absorption retardant such as a mixture of Benzyl Alcohol, Acetone and Isopropanol. Such a formulation achieves high local tissue concentration of the smooth muscle contraction substance such as oxytocin in vicinity to the site of application, via minimization of systemic absorption of the smooth muscle contraction inducing substance and at the same time via promotion of its submucosal absorption across the mucosal barrier.Type: ApplicationFiled: December 20, 2010Publication date: June 23, 2011Inventors: Filiberto Zadini, Giorgio Zadini
-
Publication number: 20110150775Abstract: The present invention provides systems for developing and/or testing therapies for prenatal diseases and conditions including Down Syndrome. The present invention also provides diagnostic methods for Down Syndrome involving, in some embodiments, gene expression analyses of fetal RNA and/or detection of expression of particular genes involved in Down Syndrome. Also provided are microarrays and kits useful in prenatal diagnostic applications.Type: ApplicationFiled: June 1, 2009Publication date: June 23, 2011Inventors: Donna Slonim, Kirby Johnson, Diana Bianchi
-
Publication number: 20110123512Abstract: The present invention is directed to method of modulating a heat shock response in a first cell of a multicellular organism comprising stimulating or inhibiting an HSR signaling activity of a second cell, wherein the second cell is a neuronal cell that regulates heat shock response activation in the first cell and that does not directly innervate the first cell.Type: ApplicationFiled: November 8, 2010Publication date: May 26, 2011Inventors: Veena Prahlad, Richard I. Morimoto
-
Publication number: 20110118349Abstract: A composition for use in treating corneal and conjunctival lesions, includes a prostaglandin F2alpha or analogue, in a therapeutic amount, the composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative. A method for treating surface ocular conditions in a patient in need thereof, includes administering an effective amount of the composition.Type: ApplicationFiled: November 19, 2010Publication date: May 19, 2011Applicant: NOVAGALI PHARMA S.A.Inventors: Jean-Sébastien GARRIGUE, Frédéric LALLEMAND, Philippe DAULL, Christophe BAUDOUIN
-
Publication number: 20110111031Abstract: The present specification provides drug delivery platforms useful for the controlled release of a compound over time in an individual.Type: ApplicationFiled: October 22, 2010Publication date: May 12, 2011Inventors: GUANG-LIANG JIANG, ADAM L. COLLETTE, REBECCA L. HORAN, JINGSONG CHEN, GREGORY H. ALTMAN, WHA BIN IM